'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases (Q44639508)

4 December 2017

'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases (English)

1 reference

4 December 2017

1 reference

Martin C Chang

1

1 reference

4 December 2017

Janet I Malowany

series ordinal

2

1 reference

4 December 2017

Julita Mazurkiewicz

series ordinal

3

1 reference

4 December 2017

Martha Wood

series ordinal

4

1 reference

4 December 2017

27 January 2012

1 reference

4 December 2017

1 reference

4 December 2017

25

1 reference

4 December 2017

5

1 reference

4 December 2017

683-688

1 reference

describes a project that uses

4 December 2017

fluorescence in situ hybridization

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.206

inferred from title

exact match

0 references

cites work

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

Standardization of HER2 testing: results of an international proficiency-testing ring study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

7 January 2021

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

7 January 2021

Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

7 January 2021

Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

7 January 2021

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

7 January 2021

Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.206

7 January 2021

10.1038/MODPATHOL.2011.206

Identifiers

DOI

1 reference

Dimensions Publication ID

4 December 2017

0 references

1 reference